Medical Oncology

Department specialty: The Medical Oncology Department was established in March 2000, has 100 open beds, and is divided into three wards, A, B, and C. It is primarily dedicated to the diagnosis and comprehensive treatment of various malignant tumors (lung cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, hepatobiliary and pancreatic tumors, gynecological tumors, tumors of the genitourinary system, head and neck tumors, melanoma, soft-tissue sarcoma, etc.). Treatments include neoadjuvant chemotherapy, postoperative chemotherapy, chemotherapy for advanced tumors, molecular targeted therapy, immunotherapy, cancer pain treatment, palliative treatment, and day chemotherapy. The department has particular expertise in managing oncologic emergencies and adverse reactions after cancer treatment. It emphasizes patients’ TNM staging and whole-course, standardized, systematic management. By implementing a multidisciplinary team (MDT) model for oncology diagnosis and treatment and conducting clinical research on new drugs, it comprehensively promotes precision treatment of malignant tumors, maximizes the overall survival of cancer patients, improves quality of life, and enhances the treatment experience. Team introduction: The department has 63 staff members. There are 20 doctors, including 6 chief physicians, 7 deputy chief physicians, 7 doctors with doctoral degrees, 3 doctoral students, 10 doctors with master’s degrees, and 9 master’s supervisors. There are 43 nursing staff, including 1 chief nurse, 8 deputy chief nurses, and 1 staff member with a master’s degree. The team includes 3 Inner Mongolia Autonomous Region Party Committee Organization Department Grassland Talents, 2 leaders of Grassland Talent Entrepreneurship and Innovation Teams, 1 recipient of the 321 Talent Project, and 3 chairpersons of provincial-level academic societies. Over the past 5 years, it has undertaken 47 projects of various types. New technologies and services: The department has mature expertise and nursing capability in ultrasound-guided PICC placement and subclavian venous catheterization. It carries out local treatment and hyperthermic perfusion treatment through thoracic and abdominal cavity catheters, four-step analgesic treatment, clinical research on new antitumor drugs, and other new technologies and services, benefiting cancer patients to the greatest extent.